Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Gilead Sciences, Inc. (GILD) Takes Lead Against AbbVie Inc (ABBV) On Crohn’s Disease Treatment

Gilead Sciences, Inc. (NASDAQ:GILD) might as well have quashed rumors making waves claiming it is planning to acquire Belgium-based Galapagos NV (ADR) (NASDAQ:GLPG). The drug maker is paying a $50 million milestone payment for the development of Crohn’s drug filgotinib, and that appears to be its main play for the moment.

Filgotinib Phase 3 Trial

Filgotinib is a JAK1-selective inhibitor designed as a novel treatment for rheumatoid arthritis, ulcerative colitis, and Crohn’s disease.  The drug is currently undergoing a Phase 3 trial as the two companies try to evaluate its efficacy and safety when used a once-a-day drug in doses of 100mg and 200mg versus a placebo administered in 1,300 patients.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

RAJ CREATIONZS / shutterstock.com

If everything goes as planned, Gilead Sciences, Inc. (NASDAQ:GILD) expects to complete the Phase 3 trial in late-2019 as it looks to get a head start with the drug ahead of AbbVie Inc (NYSE:ABBV)‘s Crohn’s disease drug ABT-494.  The drug maker is hoping for positive results on the current trials having reported disappointing clinical trial results on its ulcerative drug, GS-5745.

AbbVie vs. Gilead

Gaining approval ahead of its fierce rival is a key objective for Gilead, given that the same will go a long way in giving it an edge on the treatment of Crohn’s disease. However, AbbVie Inc (NYSE:ABBV) stands a better chance of gaining approval for ABT-494 for rheumatoid arthritis treatment, having begun clinical trials in January.

Prior to Galapagos NV (ADR) (NASDAQ:GLPG) working with Gilead, it had signed a $1.4 billion deal to develop and commercialize the drug with AbbVie in 2012. The deal was later terminated in 2015 after AbbVie Inc (NYSE:ABBV) started working on its own JAK1 inhibitor.

Follow Abbvie Inc. (NYSE:ABBV)
Trade (NYSE:ABBV) Now!

Gilead Sciences, Inc. (NASDAQ:GILD) cannot make a takeover offer for Galapagos NV (ADR) (NASDAQ:GLPG) until the end of 2017 on an agreement that was signed when it made a $425 million equity investment in the latter. The drug maker currently owns a 14.75% stake in Galapagos. The investment comes at a time when the company is under immense pressure to pursue new revenue sources as a decline in sales of its lead drugs Sovaldi and Harvoni continues to evoke concerns.

Gilead’s stock was down by 1.19% in Monday’s trading session, closing the day at lows of $74.54 a share.

Follow Gilead Sciences Inc (NASDAQ:GILD)
Trade (NASDAQ:GILD) Now!

Note: This article is written by Adam Russell and was originally published at Market Exclusive.

Loading Comments...